SARS: Systematic review of treatment effects

PLoS Medicine

Volumn 3, Issue 9, 2006, Pages 1525-1531

  Stockman, Lauren J ^a,b   Bellamy, Richard ^c   Garner, Paul ^d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; GAMMA INTERFERON; HEMOGLOBIN; IMMUNOGLOBULIN; INTERFERON; LOPINAVIR; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT ALPHA2 INTERFERON; RIBAVIRIN; RITONAVIR; STEROID;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ASPERGILLOSIS; AVASCULAR NECROSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DATA COLLECTION METHOD; DATA EXTRACTION; DIABETES MELLITUS; DRUG POTENTIATION; EPIDEMIC; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HUMAN; IN VITRO STUDY; INFECTION; LIVER DYSFUNCTION; MEDICAL EXPERT; MEDICAL RESEARCH; MORBIDITY; MORTALITY; MYCOSIS; PLASMA; PSYCHOSIS; REFERENCE DATABASE; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; SUPERINFECTION; SYSTEMATIC REVIEW; TISSUE CULTURE; TREATMENT OUTCOME; VALIDATION STUDY; VIRUS INHIBITION; VIRUS REPLICATION; WORLD HEALTH ORGANIZATION; DRUG EFFECT; SARS CORONAVIRUS;

DISEASE OUTBREAKS; HUMANS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 33749019488     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030343     Document Type: Review

References (33)

1. World Health Organization (2004) Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available: http:// www.who.int/csr/sars/country/table2004_04_21/en/index.html. Accessed 26 July 2005.
2. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348: 1953-1966.
3. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361: 1319-1325.
4. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348: 1967-1976.
5. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. (2003) The severe acute respiratory syndrome. N Engl J Med 2003: 2431-2441.
6. Leung GM, Hedley AJ, Ho LM, Chau P, Wong IO, et al. (2004) The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: An analysis of all 1755 patients. Ann Intern Med 141: 662-673.
7. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, et al. (2003) Critically ill patients with severe acute respiratory syndrome. JAMA 290: 367-373.
8. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290: 374-380.
9. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, et al. (2003) Identification of severe acute respiratory syndrome in Canada. N Engl J Med 348: 1995-2005.
10. Lee N, Hui D, Wu A, Chan P, Cameron P, et al. (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348: 1986-1994.
11. World Health Organization (2003) Future clinical trials for SARS, Informal meeting and workshop. Draft Report. Geneva: World Health Organization.
12. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. (2005) Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 326: 905-908.
13. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, et al. (2004) In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 31: 69-75.
14. Knowles SR, Phillips EJ, Dresser L, Matukas L (2003) Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 37: 1139-1142.
15. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, et al. (2003) Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289: 2801-2809.
16. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, et al. (2004) Severe acute respiratory syndrome: Report of treatment and outcome after a major outbreak. Thorax 59: 414-420.
17. Wong WM, Ho JC, Hung IF, Ng W, Lam YM, et al. (2003) Temporal patterns of hepatic dysfunction and disease severity in patients with SARS (4). JAMA 290: 2663-2665.
18. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, et al. (2004) HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 318: 719-725.
19. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, et al. (2003) Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study. Hong Kong Med J 9: 399-406.
20. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, et al. (2004). Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax 59: 252-256.
21. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, et al. (2004) Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 31: 304-309.
22. Lee DTS, Wing YK, Leung HCM, Sung JJY, Ng YK, et al. (2004) Factors associated with psychosis among patients with severe acute respiratory syndrome: A case-control study. Clin Infect Dis 39: 1247-1249.
23. Xiao JZ, Ma L, Gao J, Yang ZJ, Xing XY, et al. (2004) [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: The impact of high dosage and duration of methylprednisolone therapy]. Zhonghua Nei Ke Za Zhi 43: 179-182.
24. Li YM, Wang SX, Gao HS, Wang JG, Wei CS, et al. (2004) [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. Zhonghua Yi Xue Za Zhi 84: 1348-1353.
25. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, et al. (1987) High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317: 1565-1570.
26. Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd (1985) Early steroid therapy for respiratory failure. Arch Surg 120: 536-540.
27. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, et al. (1998) Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 280: 159-165.
28. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. (2004) Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 9: 1003-1011.
29. Sainz B Jr, Mossel EC, Peters CJ, Garry RF (2004) Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 329: 11-17.
30. Wu W, Wang JF, Liu PM, Chen WX, Yin SM, et al. (2003) [Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak]. Zhonghua Nei Ke Za Zhi 42: 453-457.
31. Li ZZ, Shen KL, Wei XM, Wang HL, Lu J, et al. (2003) [Clinical analysis of pediatric SARS cases in Beijing]. Zhonghua Er Ke Za Zhi 41: 574-577.
32. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, et al. (2005) Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 18: 1-10.
33. Wang H, Ding Y, Li X, Yang L, Zhang W, et al. (2003) Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 349: 507-508.